Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj

doi:10.1007/s40291-019-00381-6

Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

Madhav Madurantakam Royam, Chellan Kumarasamy, Siddhartha Baxi, Ajay Gupta, Nachimuthu Ramesh, Gothandam Kodiveri Muthukaliannan, Rama Jayaraj

Research output: Contribution to journal › Review article › peer-review

Abstract

Background: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting.

Objective: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways.

Methods: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran’s Q test and the I ² statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias.

Results: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug–regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428–1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%.

Conclusion: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO registration number: CRD42017082196.

Original language	English
Pages (from-to)	65-82
Number of pages	18
Journal	Molecular Diagnosis and Therapy
Volume	23
Issue number	1
Early online date	6 Feb 2019
DOIs	https://doi.org/10.1007/s40291-019-00381-6
Publication status	Published - Feb 2019

Access to Document

10.1007/s40291-019-00381-6

Cite this

Madurantakam Royam, M., Kumarasamy, C., Baxi, S., Gupta, A., Ramesh, N., Kodiveri Muthukaliannan, G., & Jayaraj, R. (2019). Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies. Molecular Diagnosis and Therapy, 23(1), 65-82. https://doi.org/10.1007/s40291-019-00381-6

@article{d98ef07d4ffd4663ac03350293aee19b,

title = "Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies",

abstract = " Background: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting. Objective: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways. Methods: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran{\textquoteright}s Q test and the I 2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias. Results: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug–regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428–1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%. Conclusion: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO registration number: CRD42017082196. ",

author = "{Madurantakam Royam}, Madhav and Chellan Kumarasamy and Siddhartha Baxi and Ajay Gupta and Nachimuthu Ramesh and {Kodiveri Muthukaliannan}, Gothandam and Rama Jayaraj",

year = "2019",

month = feb,

doi = "10.1007/s40291-019-00381-6",

language = "English",

volume = "23",

pages = "65--82",

journal = "Molecular Diagnosis and Therapy",

issn = "1177-1062",

publisher = "Adis International Ltd",

number = "1",

}

Madurantakam Royam, M, Kumarasamy, C, Baxi, S, Gupta, A, Ramesh, N, Kodiveri Muthukaliannan, G & Jayaraj, R 2019, 'Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies', Molecular Diagnosis and Therapy, vol. 23, no. 1, pp. 65-82. https://doi.org/10.1007/s40291-019-00381-6

Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies. / Madurantakam Royam, Madhav; Kumarasamy, Chellan; Baxi, Siddhartha et al.
In: Molecular Diagnosis and Therapy, Vol. 23, No. 1, 02.2019, p. 65-82.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer

T2 - A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

AU - Madurantakam Royam, Madhav

AU - Kumarasamy, Chellan

AU - Baxi, Siddhartha

AU - Gupta, Ajay

AU - Ramesh, Nachimuthu

AU - Kodiveri Muthukaliannan, Gothandam

AU - Jayaraj, Rama

PY - 2019/2

Y1 - 2019/2

N2 - Background: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting. Objective: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways. Methods: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran’s Q test and the I 2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias. Results: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug–regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428–1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%. Conclusion: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO registration number: CRD42017082196.

AB - Background: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting. Objective: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways. Methods: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran’s Q test and the I 2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias. Results: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug–regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428–1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%. Conclusion: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO registration number: CRD42017082196.

UR - http://www.scopus.com/inward/record.url?scp=85061232140&partnerID=8YFLogxK

U2 - 10.1007/s40291-019-00381-6

DO - 10.1007/s40291-019-00381-6

M3 - Review article

C2 - 30726546

AN - SCOPUS:85061232140

SN - 1177-1062

VL - 23

SP - 65

EP - 82

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

IS - 1

ER -

Madurantakam Royam M, Kumarasamy C, Baxi S, Gupta A, Ramesh N, Kodiveri Muthukaliannan G et al. Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies. Molecular Diagnosis and Therapy. 2019 Feb;23(1):65-82. Epub 2019 Feb 6. doi: 10.1007/s40291-019-00381-6

Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this